Lilly Mounjaro: The Decision Every Prospective Patient Faces

What actually happens inside the body, and why the dual mechanism matters to your decision

A common assumption is that Mounjaro is just a stronger version of semaglutide. It isn't, it works differently. Tirzepatide targets both the GLP-1 receptor and the GIP receptor, two separate pathways involved in appetite regulation, blood-sugar control and the rate at which food leaves the stomach. Semaglutide targets only GLP-1. That distinction matters clinically: in SURMOUNT-5, a head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks.

If you're weighing up which treatment to explore first, that evidence is worth knowing. But the mechanism alone doesn't decide suitability, your health history, current medicines and how your body responds to treatment are all part of the picture. The tirzepatide overview covers the pharmacology in more depth if you want to go further into the science before a consultation.

Practically speaking, treatment starts at 2.5mg. The first pen's job is to let your system adjust; it is not the dose at which most people see significant results. Prescribers step the dose upward once tolerance is established, working toward the highest dose that suits you, usually over several months.

Who Lilly's Mounjaro is licensed for in the UK (and where the NHS fits in

In the UK, tirzepatide, manufactured by Lilly, is licensed for adults with a BMI of 30 or above for weight management, or from 27 upward if at least one weight-related condition is present) conditions such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. A BMI figure alone doesn't guarantee approval; a prescriber reviews the whole clinical picture.

On the NHS, access is tightly phased. NICE's appraisal of tirzepatide (TA1026) recommends it for adults with a BMI of 35 or above plus at least one qualifying condition, and NHS England is rolling out eligibility in stages through 2025 to 2027. Many people find the NHS criteria don't yet cover them, or that waiting isn't practical. Private treatment through a regulated online pharmacy is the route for those who want to start now, provided they meet the licensed criteria.

Eli Lilly supplies Mounjaro to the UK through authorised distributor relationships; background on Eli Lilly's UK position is useful context if you're thinking about sourcing and supply chain integrity.

Cost and what it actually covers, the honest framing

Pricing for Mounjaro in the UK private market shifted significantly from September 2025, when Eli Lilly adjusted its list prices. The highest-dose pen's list price rose from around £122 to around £330 for a four-week supply; typical private prices since then range roughly £149 to £375 per month depending on dose and provider, as widely reported at the time.

That range hides a lot of variation in what's included. Some providers quote a medicine price and add consultation fees, prescription charges and delivery separately. Others bundle everything. The Mounjaro cost page breaks down exactly what to look for, and what questions to ask before you hand over payment. For a prescription medicine, the right question isn't which listing is cheapest; it's what the total price includes and whether the clinical oversight behind it is real.

At nume, one price covers the free consultation, prescription, the treatment itself, and free next-working-day tracked delivery. There are no subscriptions and no renewal fees, every repeat order goes through a fresh clinical review. If that transparency is useful, checking your eligibility takes a few minutes.

Safety signals worth weighing before you start

The most common side effects with tirzepatide are gastrointestinal: nausea, loose stools, constipation, indigestion and fatigue tend to cluster around dose increases and generally settle within a week or two. Starting at 2.5mg rather than jumping straight to a higher dose is specifically designed to reduce that early discomfort.

There are signals that require prompt attention. In January 2026 the MHRA issued a Drug Safety Update confirming acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical assessment. The MHRA Yellow Card scheme lets patients report suspected side effects directly. Women using oral contraceptives should discuss an additional non-oral method with their prescriber for the first four weeks of tirzepatide and after each dose increase, as absorption may be affected.

Mounjaro is not recommended in pregnancy, while breastfeeding, or when trying to conceive, and it is not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma, MEN2 or pancreatitis needs a careful prescriber conversation before starting, and it is also worth reading about the legal proceedings Eli Lilly has brought in connection with tirzepatide for further context on the treatment landscape. Our clinical team reviews all of this as standard before any prescription is issued, and a short video overview of how Mounjaro works is available if you prefer to see the key points explained before booking a consultation.